Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Chief Medical Officer | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.48 · Expires 2036-02-09 | Direct | 70,549 |
Reported balance
After 2026-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Disposed 70,549 · Balance 70,549 F1: 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:00 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock option (right to buy) · Derivative | 70,549 | $0.00 Strike: $13.48 | $0.00 |
DisclosureSEC source: 0001193125-26-047315 · ownership.xml · derivative · entry 1 Jaiman Manasi · CIK 0002045686 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,549 Underlying: Common Stock · 70,549 shares Expires 2036-02-09 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 126,999 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086145 · ownership.xml · derivative · entry 1 Jaiman Manasi · CIK 0002045686 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,999 Underlying: Common Stock · 126,999 shares Expires 2035-06-11 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 11, 2026, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.